Valeant Pharmaceuticals International CEO Joseph Papa's 2021 pay jumps 62% to $23M

Valeant Pharmaceuticals International reports 2021 executive compensation

By ExecPay News

Published: May 2, 2022

Valeant Pharmaceuticals International reported fiscal year 2021 executive compensation information on May 2, 2022.

In 2021, six executives at Valeant Pharmaceuticals International received on average a compensation package of $8.8M, a 53% increase compared to previous year.

Average pay of disclosed executives at Valeant Pharmaceuticals International

Joseph C. Papa, Chief Executive Officer, received $23M in total, which increased by 62% compared to 2020. 72% of Papa's compensation, or $17M, was in stock awards. Papa also received $2.4M in non-equity incentive plan, $2.3M in option awards, $1.6M in salary, as well as $30K in other compensation.

For fiscal year 2021, the median employee pay was $44,617 at Valeant Pharmaceuticals International. Therefore, the ratio of Joseph C. Papa's pay to the median employee pay was 513 to one.

Thomas J. Appio, President Co, Head Bausch + Lomb/International, received a compensation package of $10M, which increased by 166% compared to previous year. 66% of the compensation package, or $6.8M, was in stock awards.

Paul S. Herendeen, Chief Financial Officer, earned $6.9M in 2021, a 16% increase compared to previous year.

Christina M. Ackermann, General Counsel, received $4.6M in 2021, which increases by 29% compared to 2020.

Sam A. Eldessouky, Chief Financial Officer, earned $4.3M in 2021, a 229% increase compared to previous year.

Robert A. Spurr, President, U.S. Pharma Business, received $3.9M in 2021.